Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
InflaRx (IFRX) Stock Price & Analysis
602 Followers
IFRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.14 - $4.35
Previous Close$1.64
Volume65.60K
Average Volume (3M)181.63K
Market Cap
$96.57M
Enterprise Value$84.07M
Total Cash (Recent Filing)€12.77M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 01, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding58,883,272
10 Day Avg. Volume72,062
30 Day Avg. Volume181,635
Standard Deviation0.34
R-Squared0.04
Alpha-0.00670
Financial Highlights & Ratios
Price to Book (P/B)0.88
Price to Sales (P/S)1437.34
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.50Price Target Upside296.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
InflaRx News
PremiumCompany Announcements
InflaRx Announces $75M Share Sales Agreement
PremiumCompany Announcements
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial
PremiumCompany Announcements
InflaRx Unveils INF904’s Market Potential
PremiumCompany Announcements
InflaRx’s Drug Shows Life-Saving Potential in COVID-19
Bulls Say, Bears Say
Bulls Say
FDA AuthorizationGohibic received FDA Emergency Use Authorization for the treatment of critically ill COVID-19 patients.
Investor InterestAnalysts are encouraged by IFRX's measured approach with INF904 and think it could stir up increased investor interest.
Market PotentialInflaRx believes INF904 could potentially be a “pipeline in a drug” with multiple estimated multi-billion dollar market opportunities.
Bears Say
Clinical TrialsTargeting the C5a pathway in HS has failed to generate positive data in two separate randomized, placebo-controlled studies.
Financial PerformanceInflaRx reported revenues of €0.0M in 1Q24, compared to an estimate of €0.1M.
RisksCompany faces multiple risks including commercial, regulatory, development, manufacturing, financial, and liability concerns.
---
Ownership Overview
0.00%
Insiders
0.06% Mutual Funds
17.19% Other Institutional Investors
82.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.14 and its highest was $4.35 in the past 12 months.
What is InflaRx NV’s market cap?
Currently, no data Available
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Aug 01, 2024 which is in 26 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on May 08, 2024. The company reported -$0.182 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.056.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate is -$0.21.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 58,883,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.182 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of InflaRx NV?
Among the largest hedge funds holding InflaRx NV’s share is Woodline Partners LP. It holds InflaRx NV’s shares valued at N/A.
---
InflaRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (296.34% Upside)
$6.50 (296.34% Upside)
Hedge Fund Trend
Decreased
By 130.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.76%
12-Months-Change
Fundamentals
Return on Equity
-47.57%
Trailing 12-Months
Asset Growth
23.34%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
---
IFRX Stock 12 Month Forecast
Average Price Target
$6.50
▲(296.34% Upside)
Technical Analysis
Best Analysts Covering IFRX
1 Year
1 Year Success Rate
11/27 ratings generated profit
1 Year Average Return
+0.71%
reiterated a buy rating 13 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of +0.71% per trade.
---